Previous close | 12.25 |
Open | 11.76 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 11.40 - 11.76 |
52-week range | 2.87 - 17.80 |
Volume | |
Avg. volume | 102,892 |
Market cap | 14.982M |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.26 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especia
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.TRYVIO is the first oral anti-hypertensive therapy which works via a new therapeutic pathway to be approved in almost 40 years.Idorsia plans to make TRYVIO available to the millions of patients in the US who are not controlled on other drugs in t
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod, discovered by Idorsia. The upfront consideration of USD 350 million has now been fully paid by Viatris to Id